VECT-HORUS Collaborates With Sanofi In Field Of Neurodegenerative Diseases

(RTTNews) - VECT-HORUS announced the signing of a scientific collaboration agreement with SANOFI. The goal of this collaboration is to use VECT-HORUS' proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

The agreement with SANOFI is part of VECT-HORUS' framework strategy, which is to use its proprietary technology to enter into R&D agreements with biopharmaceutical companies to generate patentable new chemical entities, based on the vectorization of their drug candidates.

The blood-brain barrier (BBB) restricts very effectively the passage of imaging or therapeutic agents from blood to brain. Effectiveness of this barrier increases with the size of the molecules and as a consequence, the vast majority of the biomolecules developed by the pharmaceutical industry, including peptides, proteins, therapeutic antibodies, with promising potential in the field of brain disorders, do not cross the BBB.

Transporting drugs across the BBB is thus a technological barrier that VECT-HORUS intends to lift, allowing thereby the treatment of neurodegenerative diseases, particularly with therapeutic antibodies. The scientific approach of the company is based on the principle that the BBB is not only a physical barrier that must be crossed, but also a functional barrier whose natural transport mechanisms may be advantageously used to deliver drugs into the brain. The peptide-vectors developed by VECT-HORUS use endogenous transport mechanisms to facilitate the passage of drugs or imaging agents across the BBB, into the pathological brain.